← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
76	76 Cartesian Therapeutics RNAC $197M	44	-12	-21%	$37.3M
77	77 DELISTED Carisma Therapeutics CARM	43	-5	-10%	$43.6M
78	HTGM 78 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	43	+4	+10%	$21.5M
79	SIOX 79 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	39	-19	-33%	$19.1M
80	80 DELISTED BRAINSTORM CELL THERAPUTC BCLI	37	-1	-3%	$7.61M
81	LOGC 81 DELISTED LogicBio Therapeutics, Inc. Common Stock LOGC	37	+4	+12%	$165M
82	82 Neurogene NGNE $480M	33	-1	-3%	$39.3M
83	TCRR 83 DELISTED TCR2 Therapeutics Inc. Common Stock TCRR	33	+9	+38%	$114M
84	84 Pluri PLUR $12.5M	32	-1	-3%	$37.9M
85	85 Lunai Bioworks LNAI $3.63M	29	+11	+61%	$5.31M
86	86 Mesoblast MESO $1.8B	26	+3	+13%	$13.3M
87	87 Ocugen OCGN $280M	24	-2	-8%	$728K
88	ONCS 88 DELISTED OncoSec Medical Incorporated ONCS	20	-10	-33%	$1.57M
89	89 Imunon IMNN $5.89M	18	+1	+6%	$2.15M
90	90 Immatics IMTX $1.09B	18	+3	+20%	$55.4M
91	GMDA 91 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	17	+8	+89%	$31.8M
92	92 Opus Genetics IRD $334M	16	-12	-43%	$930K
93	93 DELISTED Orgenesis Inc. Common Stock ORGS	16	-2	-11%	$3.77M
94	94 Fulgent Genetics FLGT $591M	14	-2	-13%	$8.85M
95	95 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	13	-2	-13%	$1.12M
96	96 Capricor Therapeutics CAPR $401M	12	-5	-29%	$283K
97	97 Bionano Genomics BNGO $16M	10	0	0%	$3.3M
98	98 Eterna Therapeutics ERNA $2.53M	9	+3	+50%	$2.99M
99	CYAD 99 DELISTED Celyad Oncology SA American Depositary Shares CYAD	8	0	0%	$8.19M
100	100 Benitec Biopharma BNTC $295M	7	+1	+17%	$186K